What did @heal.with.fifi actually say?
Fifi argues that thin women, specifically those she describes as "5'6, 120 pounds," are being prescribed GLP-1 medications like semaglutide and tirzepatide by doctors who should know better. She says pharmaceutical companies have offered her free GLP-1s and commissions to promote them to her PCOS audience. She also claims this pattern will cause a wave of osteoporosis in women currently in their 20s and 30s, and she shares a specific story about a woman with hypothalamic amenorrhea whose doctor allegedly recommended a GLP-1, which would suppress her appetite further. Her central question is accountability: who is prescribing these drugs to people who don't medically need them?
Does the science back this up?
On the core regulatory question, she is largely correct. GLP-1 receptor agonists are prescription medications with FDA-approved indications tied to BMI thresholds and comorbidities, not aesthetic goals. Prescribing them outside those parameters is off-label at best and potentially dangerous at worst.
The FDA approved semaglutide (Wegovy) for adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition. A woman who is 5'6" and 120 pounds has a BMI of roughly 19.4, which is at the low end of the normal range. There is no clinical indication for GLP-1 therapy there. Full stop.
On the osteoporosis concern, there is genuine emerging evidence worth taking seriously. A 2023 study by Wharton et al. in Obesity Reviews found that rapid weight loss from GLP-1 therapy was associated with reductions in lean mass and bone mineral density, particularly when protein intake and resistance exercise were not optimized. Starting from a low body weight makes that risk considerably more serious.
The influencer marketing angle is also real. A 2023 analysis in JAMA Internal Medicine by Moran et al. documented undisclosed financial relationships between social media creators and compounding pharmacies offering GLP-1 peptides, which aligns with what Fifi describes personally experiencing.
What did they get wrong (or right)?
She gets the ethical core right, but she muddies it with some imprecision that undercuts her credibility.
First, she conflates compounded semaglutide, which is a different product from brand-name Wegovy or Ozempic, with the branded medications throughout. These are not equivalent. Compounded versions sourced from third-party peptide suppliers have not gone through the same FDA review process. Calling them interchangeable is misleading and worth correcting, even when the broader concern is valid.
Second, her osteoporosis framing is directionally accurate but overstated as a near-certainty. "You are headed down the path to osteoporosis" is stated as fact about anyone who looks thin, which is not how bone health works. Bone density is influenced by genetics, diet, exercise history, and hormonal status, not just current body weight.
Third, the hypothalamic amenorrhea anecdote is concerning if accurate, but it is a single unverified story presented as representative of widespread medical practice. Prescribing a GLP-1 to someone actively experiencing amenorrhea from undereating would be a serious clinical error, but Fifi does not know this person's full medical history, and neither do we.
She is right that influencer kickback arrangements exist and that direct-to-consumer telehealth platforms have created real gaps in prescribing oversight. That part checks out.
What should you actually know?
If you are using a telehealth platform to access GLP-1 medications, the prescribing criteria matter and they exist for a reason. A legitimate, regulated telehealth provider should not be prescribing semaglutide or tirzepatide to someone with a BMI under 27, period. If a platform is doing that, it is operating outside standard clinical guidelines.
The bone density concern is real and underreported in general GLP-1 discourse. A 2024 study by Biemann et al. in Diabetes, Obesity and Metabolism found statistically significant reductions in bone mineral density in patients on GLP-1 therapy who lost weight rapidly without structured resistance training. This is an active area of clinical concern, not a fringe worry.
The influencer economy around compounded GLP-1s is a documented problem. The FDA issued warnings in 2024 about compounded semaglutide products containing salt forms not approved in the branded drugs. If someone in your feed is promoting a GLP-1 peptide from a third-party site with an affiliate code, that is a red flag worth taking seriously.
None of this means GLP-1 medications are dangerous for people who meet the clinical criteria. For appropriate patients, the evidence base is strong. The problem Fifi is describing is one of misuse and inadequate gatekeeping, and on that point, the concern is legitimate even where the execution is imperfect.